Form 4: Veracyte Executive Sells Shares Under 10b5-1 Plan After Stock Vesting
SEC Form 4 Filing
Veracyte's Chief Commercial Officer, John Leite, sold 1,050 shares of common stock at an average price of $43.2456, following the vesting of restricted stock units and a tax withholding event.
Summary
- John Leite, Chief Commercial Officer at Veracyte, Inc., engaged in transactions involving the company's common stock.
- On December 2, 2024, 1,314 shares were withheld to cover tax obligations related to the vesting of restricted stock units.
- On December 3, 2024, 1,050 shares were sold at an average price of $43.2456, with individual sale prices ranging from $42.78 to $43.65.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 1, 2024.
- Following these transactions, Mr. Leite beneficially owns 73,810 shares of Veracyte common stock.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. The use of a 10b5-1 plan suggests a planned and expected transaction.
Industry Context
This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology and diagnostics sectors like Exact Sciences (EXAS) and Guardant Health (GH).
- These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
- The reported transactions are typical for executives who receive stock-based compensation, and the share amounts and prices are within the normal range for such transactions.
- Similar filings can be seen from executives at companies like Myriad Genetics (MYGN) and Natera (NTRA), which also operate in the molecular diagnostics space.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on investor sentiment, but the use of a 10b5-1 plan suggests the transactions were planned and not based on any new information.
Key Dates
| Date | Description |
|---|---|
| 2022-09-01 | Date of grant for 1,606 Restricted Stock Units that vested. |
| 2023-03-06 | Date of grant for 986 Restricted Stock Units that vested. |
| 2024-03-01 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 2024-12-02 | Date of tax withholding of 1,314 shares. |
| 2024-12-03 | Date of sale of 1,050 shares. |
| 2024-12-04 | Date of signature of the Form 4 filing. |
Keywords
Veracyte, insider trading, Form 4, stock sale, Rule 10b5-1, executive, share transaction, stock vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.